AR040820A1 - Composicion farmaceutica que comprende una fibra hilada electronicamente, uso de la misma y proceso para prepararla - Google Patents
Composicion farmaceutica que comprende una fibra hilada electronicamente, uso de la misma y proceso para prepararlaInfo
- Publication number
- AR040820A1 AR040820A1 AR20030102846A ARP030102846A AR040820A1 AR 040820 A1 AR040820 A1 AR 040820A1 AR 20030102846 A AR20030102846 A AR 20030102846A AR P030102846 A ARP030102846 A AR P030102846A AR 040820 A1 AR040820 A1 AR 040820A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- pharmaceutically acceptable
- active agent
- electronically
- fiber
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Textile Engineering (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Optics & Photonics (AREA)
- Heart & Thoracic Surgery (AREA)
- Mechanical Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Manufacturing & Machinery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
Composición farmacéutica que comprende una fibra hilada electrónicamente de un portador polimérico farmacéuticamente aceptable homogéneamente integrado con una forma amorfa estable de un agente activo farmacéuticamente aceptable. El agente activo puede ser un analgésico, agente anitiinflamatorio, antihelmíntico, agente antiarrítmico, antibiótico, anticoagulante, antidepresivo, agente antidiabético, antiepiléptico, antihistamina, agente antihipertensivo, agente antimuscarínico, agente antimicobacteriano, agente antineoplástico, inmunosupresor, agente antitiroideo, agente antiviral, sedante ansiolítico, astringente, agente bloqueador beta-adrenoreceptor, medio de contraste, corticosteroide, supresor de la tos diurético, dopaminérgico, homeostático, agente inmunológico, agente regulador de lípidos, relajante muscular, parasimpatomimético, paratiroide, calcitonina, prostaglandina, producto radiofarmacéutico, hormona sexual, agente antialérgico, antihistamínico, estimulante, simpatomimético, agente tiroideo, vasodilatador, inhibidor de PDE IV o una mezcla de los mismos. Preferentemente, el agente activo es aspirina, (S)-3-hidroxi-2-fenil-N-(1-fenilpropil)-4-quinolinacarboxamida; hemihidrato de 6-cetil-3,4-dihidro-2,2-dimetil-trans(+)-4-(4-fluorobenzoilamino)-2H-benzo[b]piran-3-ol, rosiglitazona, carvedilol, eposartán, hidroclorotiazida, nifedipina, ketoprofeno, indometacina, (3R, 3aS, 6aR)-hexahidrofurol[2,3-b]furan-3-il(1S, 2R)-3-[(1,3-benzodioxol-5-ilsulfonil)(isobutil)amino]-2-hidroxi-1-{4-[(2-metil-1,3-tiazol-4-il)metoxi]bencil}propilcarbamato o una sal farmacéuticamente aceptable de cualquiera de estos agentes; y está presente en una cantidad de 1 a aproximadamente 15% p / p. uso de una composición para obtener un preparado para terapia de inhalación o para dispersar en una solución acuosa. Un proceso para preparar una formulación estable de una forma amorfa de un agente farmacéuticamente activo que comprende: a) preparar una solución del agente activo, y un portador polimérico farmacéuticamente aceptable con un disolvente farmacéuticamente aceptable; o fusionar el agente activo y el portador polimérico farmacéuticamente aceptable para formar una fusión; y b) convertir la solución o la fusión del paso a) en una fibra hilada electrónicamente a través de la técnica de hilado electrónico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40172602P | 2002-08-07 | 2002-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR040820A1 true AR040820A1 (es) | 2005-04-20 |
Family
ID=31715724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AR20030102846A AR040820A1 (es) | 2002-08-07 | 2003-08-07 | Composicion farmaceutica que comprende una fibra hilada electronicamente, uso de la misma y proceso para prepararla |
Country Status (20)
Country | Link |
---|---|
US (1) | US20060013869A1 (es) |
EP (1) | EP1534250A4 (es) |
JP (1) | JP2005534716A (es) |
KR (1) | KR20050055696A (es) |
CN (1) | CN1684673A (es) |
AR (1) | AR040820A1 (es) |
AU (1) | AU2003258120B2 (es) |
BR (1) | BR0313222A (es) |
CA (1) | CA2494865A1 (es) |
IL (1) | IL166465A0 (es) |
IS (1) | IS7722A (es) |
MA (1) | MA27332A1 (es) |
MX (1) | MXPA05001499A (es) |
NO (1) | NO20051123L (es) |
NZ (1) | NZ537951A (es) |
PL (1) | PL374800A1 (es) |
RU (1) | RU2331411C2 (es) |
TW (1) | TW200410714A (es) |
WO (1) | WO2004014304A2 (es) |
ZA (1) | ZA200500563B (es) |
Families Citing this family (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050260273A1 (en) * | 2001-06-07 | 2005-11-24 | Chinea Vanessa I | Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology |
US20050271737A1 (en) * | 2001-06-07 | 2005-12-08 | Chinea Vanessa I | Application of a bioactive agent to a substrate |
US7767249B2 (en) * | 2001-06-07 | 2010-08-03 | Hewlett-Packard Development Company, L.P. | Preparation of nanoparticles |
CA2492084A1 (en) | 2002-06-27 | 2004-01-08 | Sb Pharmco Puerto Rico Inc. | Carvedilol hydobromide |
US20060083784A1 (en) * | 2002-08-07 | 2006-04-20 | Smithkline Beecham Corporation | Amorphous pharmaceutical compositions |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
EP1686986A4 (en) * | 2003-11-25 | 2009-05-27 | Sb Pharmco Inc | CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT |
US20080262224A1 (en) * | 2004-01-23 | 2008-10-23 | Smithkline Beecham Corporation | Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide |
ES2245874B1 (es) * | 2004-03-22 | 2007-08-01 | Universidad De Sevilla | Procedimiento para generar nanotubos y nanofibras compuestas a partir de chorros coaxiales. |
US20060069079A1 (en) * | 2004-09-27 | 2006-03-30 | Sever Nancy E | Stable amorphous cefdinir |
DE102004053373A1 (de) * | 2004-11-02 | 2006-05-04 | Justus-Liebig-Universität Giessen | Erfindung betreffend anisometrische Partikel in Form von Nano-/Meso-Fasern -Röhren, -Kabeln -Bändern und deren gekrümmte oder verzweigte Abwandlungen |
US7531503B2 (en) | 2005-03-11 | 2009-05-12 | Wake Forest University Health Sciences | Cell scaffold matrices with incorporated therapeutic agents |
CA2602050C (en) | 2005-03-11 | 2013-12-03 | Wake Forest University Health Sciences | Production of tissue engineered heart valves |
WO2006099332A2 (en) | 2005-03-11 | 2006-09-21 | Wake Forest University Health Sciences | Production of tissue engineered digits and limbs |
US20060204539A1 (en) | 2005-03-11 | 2006-09-14 | Anthony Atala | Electrospun cell matrices |
EP1863547B1 (en) | 2005-03-11 | 2016-05-11 | Wake Forest University Health Sciences | Tissue engineered blood vessels |
CN1300393C (zh) * | 2005-07-01 | 2007-02-14 | 中国科学院长春应用化学研究所 | 超细纤维药物剂型的乳液电纺丝制备方法 |
US8367112B2 (en) | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
WO2008023818A1 (fr) * | 2006-08-25 | 2008-02-28 | Sekisui Chemical Co., Ltd. | Fibre et procédé de production de fibre |
GB0623473D0 (en) | 2006-11-24 | 2007-01-03 | Bristol Myers Squibb Co | Dissolution and processing of cellulose |
WO2008074097A1 (en) * | 2006-12-21 | 2008-06-26 | Alphapharm Pty Ltd | Pharmaceutical compound and composition |
US20080176905A1 (en) * | 2007-01-22 | 2008-07-24 | Santiago Ini | Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof |
US20090326128A1 (en) * | 2007-05-08 | 2009-12-31 | Javier Macossay-Torres | Fibers and methods relating thereto |
US20100018641A1 (en) * | 2007-06-08 | 2010-01-28 | Kimberly-Clark Worldwide, Inc. | Methods of Applying Skin Wellness Agents to a Nonwoven Web Through Electrospinning Nanofibers |
WO2009050193A1 (en) * | 2007-10-15 | 2009-04-23 | Glaxo Group Limited | Method and apparatus for manufacturing filled linkers |
EP2209456B1 (en) * | 2007-10-15 | 2013-03-06 | Capsugel Belgium NV | Linkers for multipart dosage forms for release of one or more pharmaceutical compositions, and the resulting dosage forms |
WO2009050192A1 (en) * | 2007-10-15 | 2009-04-23 | Glaxo Group Limited | Paneled capsule shells for release of pharmaceutical compositions |
EA027333B1 (ru) * | 2007-10-17 | 2017-07-31 | Тодд Ф. Овокайтис | Стабильный при комнатной температуре некристаллический аспирин |
US8765170B2 (en) | 2008-01-30 | 2014-07-01 | The Procter & Gamble Company | Personal care composition in the form of an article |
EP2262470B1 (en) | 2008-04-16 | 2017-07-05 | The Procter & Gamble Company | Non-lathering personal care composition in the form of an article |
US20110174158A1 (en) * | 2008-05-13 | 2011-07-21 | Research Triangle Institute | Particle filter system incorporating electret nanofibers |
EP2328567A2 (de) | 2008-08-08 | 2011-06-08 | Basf Se | Wirkstoffhaltige fasernflächengebilde auf basis von biopolymeren, ihre anwendungen und verfahren zu ihrer herstellung |
JP2011530661A (ja) | 2008-08-08 | 2011-12-22 | ビーエーエスエフ ソシエタス・ヨーロピア | 活性成分の制御放出を伴う有効成分含有繊維表面構造体、その使用、およびその生産のための方法 |
CN101721751B (zh) * | 2008-10-10 | 2013-01-02 | 张阳德 | 负载了缓释细胞生长因子的具有内核的中空二氧化硅球的人体组织工程支架及其制法和用途 |
US20100291165A1 (en) * | 2008-12-08 | 2010-11-18 | Glenn Jr Robert Wayne | Personal care composition in the form of an article having a hydrophobic surface-resident coating |
US20100144228A1 (en) * | 2008-12-09 | 2010-06-10 | Branham Kelly D | Nanofibers Having Embedded Particles |
GB2466073A (en) * | 2008-12-12 | 2010-06-16 | Univ Manchester | Tissue repair scaffold |
WO2010071595A1 (en) * | 2008-12-19 | 2010-06-24 | Sekab Biofuels & Chemicals Ab | Denaturant-containing, ethanol-based liquid |
US20100291182A1 (en) * | 2009-01-21 | 2010-11-18 | Arsenal Medical, Inc. | Drug-Loaded Fibers |
GB2468503A (en) * | 2009-03-11 | 2010-09-15 | Univ Sheffield | A dressing comprising an electrospun scaffold and a nonsteroidal anti-inflammatory drug |
GB0908433D0 (en) * | 2009-05-15 | 2009-06-24 | Glaxo Group Ltd | Movel composition |
WO2011029777A1 (de) | 2009-09-11 | 2011-03-17 | Basf Se | Verfahren zur herstellung von beschichteten polymerfasern |
MX339322B (es) * | 2009-12-08 | 2016-05-20 | Procter & Gamble | Un sustrato solido, soluble y poroso y recubrimiento fijo de superficie que comprende microesferas de matriz. |
EP2536871A4 (en) | 2010-02-15 | 2013-12-18 | Univ Cornell | ELECTROFILING APPARATUS AND NANOFIBRES PRODUCED THEREWITH |
EP2536386A1 (en) | 2010-02-16 | 2012-12-26 | The Procter & Gamble Company | A porous, dissolvable solid substrate and surface resident coating comprising a zync pyrithione |
US20180163325A1 (en) | 2016-12-09 | 2018-06-14 | Robert Wayne Glenn, Jr. | Dissolvable fibrous web structure article comprising active agents |
MX2012015169A (es) * | 2010-07-02 | 2013-05-09 | Procter & Gamble | Filamentos que comprenden un agente activo sin perfume, tramas de tela no tejida y métodos para elaborarlos. |
CA2803629C (en) * | 2010-07-02 | 2015-04-28 | The Procter & Gamble Company | Filaments comprising an active agent nonwoven webs and methods for making same |
MX360481B (es) * | 2010-07-02 | 2018-11-05 | Procter & Gamble | Articulo con estructura soluble de trama fibrosa que comprende agentes activos. |
BR112013000069B1 (pt) * | 2010-07-02 | 2021-04-20 | The Procter & Gamble Company | manta de não-tecido compreendendo pluralidade de filamentos com polímero, e agente ativo, bem como método para tratar artigo de tecido |
WO2012003360A2 (en) | 2010-07-02 | 2012-01-05 | The Procter & Gamble Company | Detergent product and method for making same |
WO2012003365A1 (en) | 2010-07-02 | 2012-01-05 | The Procter & Gamble Company | Filaments comprising an ingestible active agent nonwoven webs and methods for making same |
CN103025930B (zh) | 2010-07-02 | 2014-11-12 | 宝洁公司 | 递送活性剂的方法 |
JP6203639B2 (ja) * | 2011-01-28 | 2017-09-27 | メリット・メディカル・システムズ・インコーポレイテッドMerit Medical Systems,Inc. | 電界紡糸されたptfeでコーティングされたステントおよび使用方法 |
US9102570B2 (en) | 2011-04-22 | 2015-08-11 | Cornell University | Process of making metal and ceramic nanofibers |
EP2701668A1 (en) | 2011-04-29 | 2014-03-05 | Massachusetts Institute of Technology | Layer processing for pharmaceuticals |
WO2012150265A1 (en) * | 2011-05-02 | 2012-11-08 | Dsm Ip Assets B.V. | Fiber comprising a biodegradable polymer |
EP2537538A1 (en) * | 2011-06-22 | 2012-12-26 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | Bioresorbable Wound Dressing |
CN102462673A (zh) * | 2011-07-22 | 2012-05-23 | 广东食品药品职业学院 | 一种自组装囊泡载药纳米纤维膜及其电纺制备方法 |
RU2487701C2 (ru) * | 2011-07-26 | 2013-07-20 | Общество с ограниченной ответственностью "Инмед" | Раствор для получения материала на основе хитозана, способ получения гемостатического материала из этого раствора (варианты) и медицинское изделие с использованием волокон на основе хитозана |
WO2013033367A1 (en) | 2011-08-30 | 2013-03-07 | Cornell University | Metal and ceramic nanofibers |
WO2013058751A1 (en) * | 2011-10-19 | 2013-04-25 | Virginia Tech Intellectual Properties, Inc. | Cellulose derivatives for enhancing bioavailability of flavonoids |
CN102560887B (zh) * | 2012-01-17 | 2014-01-29 | 东华大学 | 负载维生素a和e的丝素蛋白纳米纤维膜及其制备方法 |
WO2013165604A1 (en) * | 2012-05-02 | 2013-11-07 | Massachusetts Institute Of Technology | Electroprocessing of active pharmaceutical ingredients |
CN102631715A (zh) * | 2012-05-04 | 2012-08-15 | 江南大学 | 一种抗凝血纳米纤维膜的制备方法 |
JP6213975B2 (ja) * | 2012-09-13 | 2017-10-18 | テイカ製薬株式会社 | 薬物含有超極細ファイバーおよびその利用 |
US11896693B2 (en) | 2019-12-01 | 2024-02-13 | The Procter & Gamble Company | Hair conditioner compositions with a preservative system containing sodium benzoate and glycols and/or glyceryl esters |
MX370280B (es) | 2012-10-12 | 2019-12-09 | Procter & Gamble | Composición para el cuidado personal en la forma de un artículo disoluble. |
WO2014066297A1 (en) * | 2012-10-22 | 2014-05-01 | North Carolina State University | Nonwoven fiber materials |
JP6067342B2 (ja) * | 2012-11-16 | 2017-01-25 | 花王株式会社 | シート状化粧料 |
US9211290B2 (en) * | 2012-12-31 | 2015-12-15 | Noven Therapeutics, Llc | Solid dispersions of amorphous paroxetine mesylate |
WO2014142675A1 (en) | 2013-03-12 | 2014-09-18 | Active Fibres Limited | Nanofibre and bioactive compositions and related methods |
RU2522216C1 (ru) * | 2013-05-13 | 2014-07-10 | Иван Михайлович Афанасов | Многослойный материал с хитозановым слоем из нано- и ультратонких волокон |
EP2810645B1 (en) * | 2013-06-06 | 2017-05-24 | A. Sezai Sarac | New Drug Delivery System |
EP2813212A1 (en) * | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Drug formulation using API in nanofibers |
TWI480071B (zh) * | 2013-06-26 | 2015-04-11 | Univ Nat Yunlin Sci & Tech | 具有三維方向性之奈米纖維細胞導管及其無毒之製備方法與應用 |
CN103405381B (zh) * | 2013-08-23 | 2016-05-25 | 北京泰克美高新技术有限公司 | 一种制备无定型态物质的方法 |
JP6315754B2 (ja) * | 2013-10-02 | 2018-04-25 | 花王株式会社 | シート状化粧料 |
US10092679B2 (en) | 2013-10-18 | 2018-10-09 | Wake Forest University Health Sciences | Laminous vascular constructs combining cell sheet engineering and electrospinning technologies |
WO2015112812A1 (en) * | 2014-01-23 | 2015-07-30 | The University Of Florida Research Foundation, Inc. | Magnetic nanoparticle embedded nanofibrous membrane |
CA2943415C (en) * | 2014-04-22 | 2018-09-04 | The Procter & Gamble Company | Filaments and fibrous structures employing same |
WO2015164227A2 (en) | 2014-04-22 | 2015-10-29 | The Procter & Gamble Company | Compositions in the form of dissolvable solid structures |
US9827173B2 (en) | 2014-05-05 | 2017-11-28 | The Procter & Gamble Company | Porous dissolvable solid structure with two benefit agents and methods of forming an aqueous treatment liquor therefrom |
US9861559B2 (en) | 2014-05-05 | 2018-01-09 | The Procter & Gamble Company | Consumer product comprising a porous, dissolvable, fibrous web solid structure with a silicone coating |
US9867762B2 (en) | 2014-05-05 | 2018-01-16 | The Procter & Gamble Company | Consumer product comprising a porous dissolvable solid structure and silicone conditioning agent coating |
US9937111B2 (en) | 2014-05-05 | 2018-04-10 | The Procter & Gamble Company | Consumer product comprising a fibrous web solid structure with a silicone conditioning agent coating |
US10213960B2 (en) | 2014-05-20 | 2019-02-26 | Massachusetts Institute Of Technology | Plasticity induced bonding |
US10202598B2 (en) | 2014-05-30 | 2019-02-12 | Todd Frank Ovokaitys | Methods and systems for generation, use, and delivery of activated stem cells |
US10384985B2 (en) | 2014-06-06 | 2019-08-20 | B.K. Consultants, Inc. | Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants |
US10040728B2 (en) | 2014-06-06 | 2018-08-07 | Todd Frank Ovokaitys | Methods and compositions for increasing the bioactivity of nutrients |
CN105362269A (zh) * | 2014-09-01 | 2016-03-02 | 天津药物研究院 | 一种含蔗糖的罗氟司特片及其制备方法 |
CN104383596A (zh) * | 2014-10-24 | 2015-03-04 | 东华大学 | 一种tpgs载药脂质体-天然材料复合纳米纤维支架的制备方法 |
WO2017085264A1 (en) * | 2015-11-19 | 2017-05-26 | Dermtreat Aps | A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site |
EP3570821B1 (en) * | 2017-01-23 | 2021-07-21 | AFYX Therapeutics A/S | Method for fabrication of a two-layered product based on electrospun fibres |
KR102595001B1 (ko) | 2017-01-23 | 2023-10-26 | 에이에프와이엑스 테라퓨틱스 에스에이 | 높은 함량의 생체접착성 물질을 가지는 전기방사 섬유의 제조 방법 |
MX2019008762A (es) | 2017-01-27 | 2019-09-18 | Procter & Gamble | Composiciones en la forma de estructuras solidas solubles. |
JP6882519B2 (ja) | 2017-01-27 | 2021-06-02 | ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company | 発泡性凝集粒子を含む溶解性固形構造体形態の組成物 |
JP2018177724A (ja) * | 2017-04-18 | 2018-11-15 | 花王株式会社 | 外用薬 |
MX2019013048A (es) | 2017-05-16 | 2019-12-11 | Procter & Gamble | Composiciones acondicionadoras para el cuidado del cabello en la forma de estructuras solidas solubles. |
CN107447366A (zh) * | 2017-08-03 | 2017-12-08 | 东华大学 | 一种pH敏感载药缓释纳米纤维膜及其制备方法和应用 |
EP3743503A1 (en) | 2018-01-26 | 2020-12-02 | The Procter & Gamble Company | Water-soluble articles and related processes |
WO2019147532A1 (en) | 2018-01-26 | 2019-08-01 | The Procter & Gamble Company | Water-soluble unit dose articles comprising perfume |
CA3087284C (en) | 2018-01-26 | 2023-05-02 | The Procter & Gamble Company | Water-soluble unit dose articles comprising enzyme |
US20190233785A1 (en) | 2018-01-26 | 2019-08-01 | The Procter & Gamble Company | Water-soluble unit dose articles comprising perfume |
WO2019168829A1 (en) | 2018-02-27 | 2019-09-06 | The Procter & Gamble Company | A consumer product comprising a flat package containing unit dose articles |
RU2671738C1 (ru) * | 2018-02-28 | 2018-11-06 | Общество с ограниченной ответственностью "Фибрасофт" | Способ получения свободно позиционируемых пленок методом электроспиннинга |
CN108635336A (zh) * | 2018-04-04 | 2018-10-12 | 浙江大学 | 一种混合柔性缓释口服胶囊 |
CN108403657A (zh) * | 2018-04-04 | 2018-08-17 | 浙江大学 | 一种口服胶囊 |
CN108635337A (zh) * | 2018-04-04 | 2018-10-12 | 浙江大学 | 一种柔性复合缓释口服胶囊 |
US11992560B2 (en) * | 2018-06-14 | 2024-05-28 | Alma Mater Studiorum—Università di Bologna | Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug |
EP3583954A1 (en) * | 2018-06-19 | 2019-12-25 | neubourg skin care GmbH | Nanodispersions of birch bark extract, electrospun fibers containing such nanodispersions and their use for the treatment of wounds |
JP1629688S (es) | 2018-07-16 | 2019-04-15 | ||
US10982176B2 (en) | 2018-07-27 | 2021-04-20 | The Procter & Gamble Company | Process of laundering fabrics using a water-soluble unit dose article |
US11666514B2 (en) | 2018-09-21 | 2023-06-06 | The Procter & Gamble Company | Fibrous structures containing polymer matrix particles with perfume ingredients |
US11859338B2 (en) | 2019-01-28 | 2024-01-02 | The Procter & Gamble Company | Recyclable, renewable, or biodegradable package |
EP3712237A1 (en) | 2019-03-19 | 2020-09-23 | The Procter & Gamble Company | Fibrous water-soluble unit dose articles comprising water-soluble fibrous structures |
MX2021013141A (es) | 2019-06-28 | 2021-12-10 | Procter & Gamble | Articulos fibrosos solidos disolubles que contienen surfactantes anionicos. |
CN114025738A (zh) | 2019-07-03 | 2022-02-08 | 宝洁公司 | 包含阳离子表面活性剂和可溶性酸的纤维结构 |
USD939359S1 (en) | 2019-10-01 | 2021-12-28 | The Procter And Gamble Plaza | Packaging for a single dose personal care product |
EP4045425B1 (en) | 2019-10-14 | 2024-03-06 | The Procter & Gamble Company | Biodegradable and/or home compostable sachet containing a solid article |
WO2021097691A1 (en) | 2019-11-20 | 2021-05-27 | The Procter & Gamble Company | Porous dissolvable solid structure |
CN111020880A (zh) * | 2019-12-04 | 2020-04-17 | 广西民族大学 | 结肠靶向盐酸青藤碱缓释纳米纤维膜及其制备方法和应用 |
USD962050S1 (en) | 2020-03-20 | 2022-08-30 | The Procter And Gamble Company | Primary package for a solid, single dose beauty care composition |
USD941051S1 (en) | 2020-03-20 | 2022-01-18 | The Procter And Gamble Company | Shower hanger |
USD965440S1 (en) | 2020-06-29 | 2022-10-04 | The Procter And Gamble Company | Package |
CN115867357A (zh) | 2020-07-31 | 2023-03-28 | 宝洁公司 | 用于毛发护理的含有球粒的水溶性纤维小袋 |
WO2022036352A1 (en) | 2020-08-11 | 2022-02-17 | The Procter & Gamble Company | Clean rinse hair conditioner compositions containing brassicyl valinate esylate |
EP4196233A1 (en) | 2020-08-11 | 2023-06-21 | The Procter & Gamble Company | Moisturizing hair conditioner compositions containing brassicyl valinate esylate |
WO2022036354A1 (en) | 2020-08-11 | 2022-02-17 | The Procter & Gamble Company | Low viscosity hair conditioner compositions containing brassicyl valinate esylate |
JP2023553395A (ja) | 2020-12-01 | 2023-12-21 | ザ プロクター アンド ギャンブル カンパニー | 可溶化抗ふけ活性物質を含有する水性ヘアコンディショナー組成物 |
WO2023117590A1 (en) * | 2021-12-21 | 2023-06-29 | Universiteit Gent | Solution electrospun fibers, compositions comprising the same and a process of manufacturing thereof |
WO2023145886A1 (ja) * | 2022-01-31 | 2023-08-03 | 三菱ケミカル株式会社 | ナノファイバー |
CN114522166B (zh) * | 2022-04-22 | 2022-09-30 | 北京剂泰医药科技有限公司 | 一种固体分散体组合物及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US17208A (en) * | 1857-05-05 | Improvement in heating feed-water apparatus of locomotives | ||
US5024789A (en) * | 1988-10-13 | 1991-06-18 | Ethicon, Inc. | Method and apparatus for manufacturing electrostatically spun structure |
US5311884A (en) * | 1991-11-12 | 1994-05-17 | Ethicon, Inc. | Process for making a piezoelectric biomedical device |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5980941A (en) * | 1997-08-20 | 1999-11-09 | Fuisz Technologies Ltd. | Self-binding shearform compositions |
US6106913A (en) * | 1997-10-10 | 2000-08-22 | Quantum Group, Inc | Fibrous structures containing nanofibrils and other textile fibers |
US6110590A (en) * | 1998-04-15 | 2000-08-29 | The University Of Akron | Synthetically spun silk nanofibers and a process for making the same |
CA2396640A1 (en) * | 2000-01-28 | 2001-08-02 | Smithkline Beecham Corporation | Electrospun pharmaceutical compositions |
CA2464092C (en) * | 2000-10-18 | 2013-03-12 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessing in drug delivery and cell encapsulation |
WO2003099230A2 (en) * | 2002-05-28 | 2003-12-04 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
-
2003
- 2003-08-05 TW TW092121421A patent/TW200410714A/zh unknown
- 2003-08-07 NZ NZ537951A patent/NZ537951A/en unknown
- 2003-08-07 WO PCT/US2003/024641 patent/WO2004014304A2/en active Application Filing
- 2003-08-07 RU RU2005106261/15A patent/RU2331411C2/ru not_active IP Right Cessation
- 2003-08-07 EP EP03784959A patent/EP1534250A4/en not_active Withdrawn
- 2003-08-07 MX MXPA05001499A patent/MXPA05001499A/es unknown
- 2003-08-07 PL PL03374800A patent/PL374800A1/xx not_active Application Discontinuation
- 2003-08-07 CN CNA038232375A patent/CN1684673A/zh active Pending
- 2003-08-07 US US10/523,835 patent/US20060013869A1/en not_active Abandoned
- 2003-08-07 CA CA002494865A patent/CA2494865A1/en not_active Abandoned
- 2003-08-07 BR BR0313222-6A patent/BR0313222A/pt not_active IP Right Cessation
- 2003-08-07 KR KR1020057002071A patent/KR20050055696A/ko not_active Application Discontinuation
- 2003-08-07 AR AR20030102846A patent/AR040820A1/es not_active Application Discontinuation
- 2003-08-07 JP JP2004527797A patent/JP2005534716A/ja active Pending
- 2003-08-07 AU AU2003258120A patent/AU2003258120B2/en not_active Expired - Fee Related
-
2005
- 2005-01-20 ZA ZA200500563A patent/ZA200500563B/xx unknown
- 2005-01-24 IL IL16646505A patent/IL166465A0/xx unknown
- 2005-02-04 MA MA28092A patent/MA27332A1/fr unknown
- 2005-03-01 IS IS7722A patent/IS7722A/is unknown
- 2005-03-02 NO NO20051123A patent/NO20051123L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA05001499A (es) | 2005-04-19 |
ZA200500563B (en) | 2006-07-26 |
CN1684673A (zh) | 2005-10-19 |
CA2494865A1 (en) | 2004-02-19 |
MA27332A1 (fr) | 2005-05-02 |
TW200410714A (en) | 2004-07-01 |
IS7722A (is) | 2005-03-01 |
KR20050055696A (ko) | 2005-06-13 |
IL166465A0 (en) | 2006-01-15 |
WO2004014304A3 (en) | 2004-06-24 |
NO20051123L (no) | 2005-05-06 |
US20060013869A1 (en) | 2006-01-19 |
BR0313222A (pt) | 2005-06-14 |
EP1534250A4 (en) | 2007-07-04 |
PL374800A1 (en) | 2005-10-31 |
AU2003258120B2 (en) | 2009-02-26 |
AU2003258120A1 (en) | 2004-02-25 |
NZ537951A (en) | 2007-12-21 |
EP1534250A2 (en) | 2005-06-01 |
WO2004014304A2 (en) | 2004-02-19 |
RU2331411C2 (ru) | 2008-08-20 |
RU2005106261A (ru) | 2005-08-10 |
JP2005534716A (ja) | 2005-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR040820A1 (es) | Composicion farmaceutica que comprende una fibra hilada electronicamente, uso de la misma y proceso para prepararla | |
CN100430069C (zh) | 一种中药及其复方的可逆性热凝胶化水性药物组合物 | |
Malke et al. | Formulation and Evaluation of Oxcarbazepine Fast Dissolve Tablets. | |
JP2008501655A5 (es) | ||
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
CA2388610A1 (en) | Oral transmucosal drug dosage using solid solution | |
JP2005512995A5 (es) | ||
WO2005117895A2 (en) | Compositions comprising meloxicam | |
AR019935A1 (es) | Preparacion solida de desintegracion rapida, uso de una hidroxipropil celulosa poco sustituida en dicha preparacion y metodo para mejorar la capacidad dedesintegracion rapida de la misma | |
BRPI0514180A (pt) | composto, composição farmacêutica, uso de um composto, kit farmaceuticamente útil adaptado para administração oral diária, e, métodos de preparação de um composto, e de contracepção em um mamìfero | |
CO5170471A1 (es) | Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio | |
ES2804324T3 (es) | Composiciones que contienen extractos de Curcuma longa y Equinácea angustifolia que son útiles para reducir la inflamación y el dolor periféricos | |
EP1885333A1 (en) | Pharmaceutical formulation of apomorphine for buccal administration | |
CO4750658A1 (es) | Formulaciones farmaceuticas y procedimientos que comprenden amoxicilina y una sal de acido clavulanico | |
CN101080235A (zh) | 包含血根草属或博落回属提取物的组合物 | |
PE20040973A1 (es) | Composiciones de anti-histaminicos, descongestivos y drogas anti-inflamatorias no esteroidales | |
CN1606445A (zh) | 用于局部传递环加氧酶-2酶抑制剂的药物组合物的制备方法 | |
AR029154A1 (es) | Una tableta de liberacion controlada que comprende betahistina y un proceso para la preparacion de dicha tableta | |
CO5640085A2 (es) | Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato | |
HUP0203148A2 (hu) | Mirtazapint tartalmazó orálisan dezintegrálódó készítmény | |
Özdemir et al. | Treatment of alcohol withdrawal syndrome | |
BR0008054A (pt) | Forma cristalina de eplerenona | |
AR033807A1 (es) | Uso de (r)-(-)-2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y de sus sales aceptables para uso fisiologico, y las composiciones farmaceuticas que contiene estos compuestos | |
JP2013049729A (ja) | 医薬組成物 | |
JP3987501B2 (ja) | 医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |